Trial Profile
An Open-Label Adaptive-Design Study of Intracisternal Adenoassociated Viral Vector Serotype rh.10 Carrying the Human β-Galactosidase cDNA for Treatment of GM1 Gangliosidosis
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Lixmabegagene relduparvovec (Primary)
- Indications Gangliosidoses
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors LYSOGENE
- 09 Jun 2023 This trial has been Discontinued in France, according to European Clinical Trials Database record.
- 07 Jun 2023 Status changed from active, no longer recruiting to discontinued.
- 30 Aug 2022 Planned End Date changed from 1 Jun 2025 to 1 Jan 2030.